Skip to main content
. 2017 Apr 4;127(5):1813–1825. doi: 10.1172/JCI91816

Figure 2. Co-transplantation of donor ILC2s reduces aGVHD incidence.

Figure 2

Lethally irradiated B6D2 mice received TCD BM (BM only), BM plus total splenic T cells (BM + T cells), or BM plus T cells with activated ILC2s (BM, T cells + WT ILC2). (A) Kaplan-Meier plot of survival following allo-SCT; 1 representative of 3 experiments shown (n = 8 each experiment). Log-rank (Mantel-Cox) test, ***P < 0.001. (B) Clinical score and (C) percentage of body weight change after transplantation. Two-way ANOVA, with Bonferroni correction for repeated measures of multiple comparisons, ***P < 0.001. (D) Pathology scores of histological evaluations of GVHD target organs, 20 days after BMT (n = 4 mice per group). Student’s t test with Welch’s correction, *P < 0.05. (E) Kaplan-Meier plot for irradiated BALB/c mice that received TCD BM (BM only), BM plus splenic T cells (BM + T cells), or BM plus T cells with ILC2s (BM, T cells + WT ILC2). Results represent 2 independent experiments; n = 14. Log-rank (Mantel-Cox) test, ***P < 0.001. (F) Kaplan-Meier plot for B6D2 recipients that received BM alone (BM only), BM and splenic T cells (BM + T cells), and WT ILC2s either at the time of transplant (BM, T cells + WT ILC2 [day 0]) or 7 days after transplant (BM, T cells + WT ILC2 [day 7]); data represent 2 experiments; n = 12 total in each group. Log-rank (Mantel-Cox) test, ***P < 0.001. (G) Clinical score of recipients from Figure 2F. Two-way ANOVA, with Bonferroni correction for repeated measures of multiple comparisons, **P < 0.01.